by Chris Wack
Vaxxinity Inc. stated that after the completion of Part A of the Phase 1 trial in healthy volunteers, the first patient with Parkinson’s disease has been dosed with UB-312 in Part B of a double-blind, placebo-controlled Phase 1 clinical trial.
The company said its UB-312 is a synthetic peptide vaccine that targets toxic forms of aggregated alpha-synuclein, a protein that plays a central role in synaptic functions and regulation of neurotransmitter release at the synapse. Mutations of ASIN increase the risk of developing PD and other synucleinopathies, including dementia with Lewy bodies as well as multiple system atrophy.
UB-312 was given an orphan designation for MSA by the European Medicines Agency.
Vaccinity said Part A of its Phase 1 study demonstrated that UB-312 was generally safe and well tolerated at multiple dosage levels, and that it successfully generated robust levels of titers against aggregated ASINs. which crosses the blood-brain barrier at a significant level of 0.2%.
The study is enrolling 20 patients with Parkinson’s, Hohen and Yahr stages at the Center for Human Drug Research in the Netherlands. Patients will be enrolled in one of two dosage groups with the primary objectives of safety and immunogenicity.
Shares of Vaxxinity were up 3% to $6 in premarket trading.
Write to Chris Wack at [email protected]